Ipamorelin
Also known as: NNC 26-0161, IPA, Ipamorelin acetate, Aib-His-D-2-Nal-D-Phe-Lys-NH2
Growth Hormone Secretagogue (GHS); Ghrelin Receptor Agonist; Synthetic Pentapeptide
What it is
Ipamorelin is a peptide people use to boost their body's own growth hormone output. It's taken for muscle recovery, body composition, better sleep, and recovery after illness or surgery. Not FDA-approved; classified as investigational.
The scientific side
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor (GHS-R1a), stimulating growth hormone (GH) release from the anterior pituitary. Its GH-releasing potency and efficacy in vitro are similar to GHRP-6 (EC50 = 1.3 nmol/L), and it stimulates GH release via a GHRP-like receptor mechanism. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate ACTH or cortisol at doses more than 200-fold above its GH-releasing ED50 in swine, making it the first described GHS with selectivity for GH release analogous to GHRH. Pharmacokinetic-pharmacodynamic modeling in healthy male volunteers demonstrated dose-proportional kinetics with a short terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and volume of distribution at steady state of 0.22 L/kg; it induces a single episode of GH release peaking at ~0.67 hours. Ipamorelin is described as a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair pathways. It also exerts GI promotility effects via ghrelin receptor-mediated cholinergic mechanisms, stimulates insulin secretion via calcium channel and adrenergic receptor pathways, and may act peripherally to attenuate visceral and somatic nociception.
Class: Growth Hormone Secretagogue (GHS); Ghrelin Receptor Agonist; Synthetic Pentapeptide
At a glance
| What it is | A synthetic 5-amino-acid peptide that triggers growth hormone release through the ghrelin receptor. |
|---|---|
| FDA status | Not approved for any use. On FDA's list of compounding substances with significant safety risks (503B, since 2023). |
| Used for | Raising growth hormone and IGF-1 for recovery, body composition and sleep, without direct human evidence for those uses. |
| Human evidence | One PK study in 40 healthy men and two IV trials for post-surgical bowel recovery; the published one missed its main goal. |
| Half-life | About 2 hours (IV, healthy men). |
| Banned in sport | Yes. WADA names it under S2.2.4 (growth hormone releasing factors), prohibited at all times. |
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (5 amino acids) developed by Novo Nordisk in the 1990s under the code NNC 26-0161. It belongs to the growth hormone-releasing peptides (GHRPs), alongside GHRP-6 and GHRP-2.
It is often paired with a GHRH analog such as CJC-1295, which acts on a different pituitary receptor.
Sources: [1]
How does it work?
Ipamorelin activates the ghrelin receptor (GHS-R1a) on the pituitary, which releases a pulse of growth hormone. Growth hormone then raises IGF-1.
What made it stand out was selectivity. In pigs, older GHRPs raised ACTH and cortisol, but "ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation", even at doses over 200 times the effective dose. None of the peptides tested changed FSH, LH, prolactin or TSH. These are animal results; they have not been confirmed in human trials.
Pharmacokinetics
| Half-life | About 2 hours (terminal; IV in 40 healthy men) |
|---|---|
| Metabolism | Moderately resistant to breakdown: 60-80% of the dose recovered from bile and urine as intact peptide in rats |
| Clearance | 0.078 L/h/kg in healthy men (IV); excreted mainly in urine in rats |
| Route | Studied IV in humans; sold for injection under the skin |
Is it FDA-approved?
No. Ipamorelin has never been approved for any use.
FDA added ipamorelin acetate to its list of compounding substances with significant safety risks (503B Category 2) in September 2023. FDA cited immunogenicity and its unnatural amino acids, and noted that "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility". That refers to IV use in hospitalized surgical patients, not to the injections people take at home, for which FDA says it has no safety information.
In October 2024, FDA's Pharmacy Compounding Advisory Committee voted 0-12, with 1 abstention, against adding ipamorelin to the 503A bulks list.
- WADA: S2.2.4 Growth hormone releasing factors (named among growth hormone secretagogues; prohibited at all times)
History
Novo Nordisk published ipamorelin in 1998 as "the first selective growth hormone secretagogue", and a 1999 study in 40 healthy men described its pharmacokinetics.
Development then moved to Helsinn, which tested IV ipamorelin to speed bowel recovery after surgery (postoperative ileus). The phase 2 trial, run from 2008 to 2009 and published in 2014, did not meet its main goal, and no company has pursued approval since. Ipamorelin now circulates mainly as an unregulated research peptide.
Regulatory timeline
- September 29, 2023FDA places ipamorelin acetate in Category 2 for 503B outsourcing facilities, citing immunogenicity, unnatural amino acids and serious adverse events with IV use for gastric motility. Source
- October 29, 2024FDA's Pharmacy Compounding Advisory Committee votes 0-12, with 1 abstention, against adding ipamorelin (free base and acetate) to the 503A bulks list. Source
- As of October 2026Still in 503B Category 2 and not FDA-approved. It was not on the July 2026 advisory committee agenda. Source
Side effects
In the published ileus trial (114 surgical patients, IV 0.03 mg/kg twice daily for up to 7 days), adverse events were common in both groups (87.5% on ipamorelin versus 94.8% on placebo), and the authors judged it well tolerated. FDA's note about serious adverse events including death comes from this IV, post-surgical setting.
There are no published trials of the under-the-skin injections people use, so their side effects are not known from controlled data. Because it raises growth hormone and IGF-1, effects seen with other growth hormone secretagogues, such as water retention and higher blood sugar, are plausible but unstudied.
Who should not use it
- No established contraindications: ipamorelin has never been through approval trials.
- Competitive athletes: prohibited at all times under WADA S2.2.4.
- Active cancer: it raises growth hormone and IGF-1, growth factors that approved GH-releasing drugs list as a contraindication.
- Pregnancy and breastfeeding: not studied.
Only one published efficacy trial: 114 surgical patients given IV ipamorelin or placebo; treatment-emergent adverse events 87.5% vs 94.8%.
What does the research show?
In rats and pigs, ipamorelin released growth hormone about as strongly as GHRP-6 but more selectively. In 40 healthy men given IV doses, it had a terminal half-life of about 2 hours and raised growth hormone in proportion to the dose.
The only published efficacy trial tested it after bowel surgery: median time to tolerate a solid meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, not a significant difference (p = 0.15). No published human trial has measured muscle, fat loss, sleep or anti-aging outcomes.
Studied for
- Postoperative ileus after bowel surgery (phase 2, IV; missed its main goal)
- Growth hormone release and selectivity (rats and pigs)
- Pharmacokinetics in healthy men (IV)
FAQ
Is Ipamorelin FDA-approved?
No. It has never been approved for any use, and its one published efficacy trial missed its main goal.
Sources: [6]
Did people die from Ipamorelin?
FDA notes serious adverse events including death in a study where ipamorelin was given IV to improve gut motility, in hospitalized surgical patients. That is a different setting from home injections, and the published trial reported similar adverse-event rates on ipamorelin and placebo.
Does Ipamorelin raise cortisol or prolactin?
Not in the animal studies that defined it: in pigs it did not raise ACTH or cortisol beyond GHRH levels, and it did not change prolactin, FSH, LH or TSH. This has not been tested in human trials.
Sources: [1]
Can a compounding pharmacy make Ipamorelin?
FDA lists ipamorelin acetate as a significant safety risk for 503B outsourcing facilities, and its advisory committee voted 0-12 against adding it to the 503A bulks list in 2024.
What is Ipamorelin's half-life?
About 2 hours after IV dosing in healthy men. There is no published human data for under-the-skin injection.
Sources: [2]
Is Ipamorelin banned in sport?
Yes. The 2026 WADA Prohibited List names ipamorelin under S2.2.4, prohibited at all times.
Sources: [8]
Does Ipamorelin build muscle or burn fat?
There is no human trial evidence. No published human study has measured body composition with ipamorelin.
Sources: [6]
Citations
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
- Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998. PMID 9879640
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024. fda.gov/media/185412/download
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. PMID 25331030
- NCT00672074: Safety and efficacy of ipamorelin for management of post-operative ileus (Helsinn). clinicaltrials.gov/study/NCT00672074
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Raun 1998. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. pubmed.ncbi.nlm.nih.gov/9849822
- Johansen 1998. Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998. pubmed.ncbi.nlm.nih.gov/9879640
- Gobburu 1999. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. pubmed.ncbi.nlm.nih.gov/10496658
- Beck 2014. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. pubmed.ncbi.nlm.nih.gov/25331030
- ClinicalTrials.gov. NCT00672074: Safety and efficacy of ipamorelin for management of post-operative ileus (Helsinn). clinicaltrials.gov/study/NCT00672074
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA PCAC, October 2024. FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024. fda.gov/media/185412/download
- FDA PCAC, July 2026. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (agenda). fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Intravenous infusion (PMID: 2533103010496658192895671062916527186127)Subcutaneous injection (PMID: 10373343117352441082884011162489)Subcutaneous via osmotic minipump (PMID: 10828840)Intraperitoneal injection (PMID: 39043357)Intranasal (pharmacokinetic study in rats~20% bioavailability) (PMID: 9879640)Nasal administration in humans (excretion/metabolite study) (PMID: 25869809)
- Storage
- One abstract notes that -20°C is the appropriate storage temperature for small peptides including ipamorelin in urine samples for sports drug testing purposes. No abstract specifies storage conditions for pharmaceutical preparations of ipamorelin intended for clinical or research use.
- Cautions
- Ipamorelin is not approved by the FDA or other major regulatory agencies for performance or musculoskeletal indications; use outside of approved/investigational protocols carries unknown safety risks.,Long-term safety data in humans are absent; reviewed literature notes a 'current lack of clinical trials' and that 'rigorous human safety data are scarce'.,Gray-market peptide products may be mislabeled, contaminated, or contain analogs (e.g., Gly-Ipamorelin) with unknown pharmacological and safety profiles.,Ipamorelin is listed on the WADA Prohibited List; athletes should be aware of antidoping implications and detection in urine.,Reported adverse effects class-wide for GHS include endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, musculoskeletal symptoms, and injection-site reactions.,Sterile technique for any injection is essential; use of unregulated supply chain products introduces additional contamination risks.
Legal & regulatory status
Not stated in reviewed literature as FDA-approved for any indication. Reviewed literature describes ipamorelin as an unapproved/investigational compound for performance and musculoskeletal indications. A Phase II RCT…
Listed on the WADA Prohibited List as a prohibited substance (PMID: 13578461 [not in corpus]; per PMID: 26578461, ipamorelin is listed among prohibited substances <2 kDa on the WADA Prohibited List; PMID: 41880199 notes…
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Growth hormone stimulation / GH-IGF-1 axis modulation Mixed
- Ipamorelin is the first selective GHS; releases GH in rats and swine with potency and efficacy comparable to GHRP-6 but without significant ACTH or cortisol elevation even at >200-fold above the GH ED50. PMID 9849822 Raun K et al. European Journal of Endocrinology (1998)
- PK/PD study in healthy male volunteers: dose-proportional pharmacokinetics, terminal half-life ~2 h, single episode of GH release peaking at 0.67 h. SC50 for half-maximal GH stimulation = 214 nmol/L. PMID 10496658 Gobburu JV et al. Pharmaceutical Research (1999)
- Ipamorelin (18–450 µg/day s.c., 3×/day, 15 days) dose-dependently increased longitudinal bone growth rate and body weight in adult female rats. Total IGF-I levels and serum bone markers were unaffected. PMID 10373343 Johansen PB et al. Growth Hormone & IGF Research (1999)
- Postoperative ileus / gastrointestinal motility Human RCT
- Phase II multicenter double-blind RCT (n=114): ipamorelin 0.03 mg/kg IV twice daily for up to 7 days after bowel resection was well tolerated. Median time to first tolerated meal: 25.3 h (ipamorelin) vs 32.6 h (placebo); difference not statistically significant (p=0.15). PMID 25331030 Beck DE et al. International Journal of Colorectal Disease (2014)
- In a rodent model of POI, single IV dose of ipamorelin (1 mg/kg) decreased time to first bowel movement; repetitive dosing (0.1 or 1 mg/kg, 4×/day, 2 days) significantly increased fecal output, food intake, and body weight. PMID 19289567 Venkova K et al. Journal of Pharmacology and Experimental Therapeutics (2009)
- Ipamorelin (0.014 µmol/kg IV) significantly accelerated gastric emptying in a rat model of gastroparesis compared to vehicle (52% vs 78% meal remaining in stomach at 15 min). Acts via ghrelin receptor-mediated cholinergic mechanism. PMID 27186127 Greenwood-Van Meerveld B et al. Journal of Experimental Pharmacology (2012)
- Counteracting glucocorticoid-induced muscle and bone catabolism Animal studies only
- In adult female rats, ipamorelin (100 µg/kg s.c. 3×/day, 3 months) combined with methylprednisolone significantly increased maximum tetanic tension and increased periosteal bone formation rate 4-fold compared to glucocorticoid alone. PMID 11735244 Andersen NB et al. Growth Hormone & IGF Research (2001)
- Ipamorelin (0.5 mg/kg/day, 7 days) in prednisolone-treated rats reduced hepatic urea cycle enzyme expression, reduced capacity of urea-N synthesis by 20%, neutralized nitrogen balance, and normalized organ N-contents, though less efficiently than GH at the doses given. PMID 19231263 Aagaard NK et al. Growth Hormone & IGF Research (2009)
- Ipamorelin IV (0.4 or 1.6 mg/kg/day, 4×/day, 10 days) in methylprednisolone-treated rats significantly reduced body weight loss and increased IGF-I levels compared to methylprednisolone alone. Methylprednisolone did not disrupt the GH response to ipamorelin. PMID 10629165 Malmlöf K et al. Growth Hormone & IGF Research (1999)
- Bone mineral content and longitudinal bone growth Animal studies only
- Ipamorelin (0.5 mg/kg/day s.c. via osmotic minipump, 12 weeks) increased total tibial and vertebral bone mineral content by DXA in adult female rats; increased cortical BMC was due to increased cross-sectional bone area; volumetric BMD was unchanged. PMID 10828840 Svensson J et al. Journal of Endocrinology (2000)
- Ipamorelin (18–450 µg/day s.c. 3×/day, 15 days) dose-dependently increased longitudinal bone growth rate from 42 to 52 µm/day in adult female rats. PMID 10373343 Johansen PB et al. Growth Hormone & IGF Research (1999)
- Musculoskeletal recovery / performance enhancement (combined with CJC-1295) Animal studies only
- CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss; findings limited to animal studies with no validated human orthopaedic evidence. PMID 41476424 Mayfield CK et al. American Journal of Sports Medicine (2026)
- Visceral and somatic pain attenuation Animal studies only
- Ipamorelin administered intravenously significantly attenuated colonic hypersensitivity and somatic allodynia in a rat model of non-inflammatory visceral hypersensitivity; anti-nociceptive effects were blocked by a ghrelin receptor antagonist. Ipamorelin was described as a peripherally restricted ghrelin mimetic. PMID 32257855 Mohammadi EN et al. Journal of Experimental Pharmacology (2020)
- Cisplatin-induced weight loss and cachexia prevention Animal studies only
- Ipamorelin (1–3 mg/kg i.p.) in ferrets inhibited cisplatin-induced weight loss during the delayed phase (48–72 h) by approximately 24%. No anti-emetic effect was observed with intraperitoneal ipamorelin. PMID 39043357 Lu Z et al. Physiology & Behavior (2024)
- Insulin secretion stimulation In vitro only
- Ipamorelin (10⁻¹²–10⁻⁶ M) significantly increased insulin secretion from pancreatic tissue fragments of normal and streptozotocin-diabetic rats in vitro. Effect was inhibited by diltiazem, yohimbine, propranolol, and (in diabetic rats) atropine, suggesting calcium channel and adrenergic receptor involvement. PMID 15665799 Adeghate E, Ponery AS. Neuro Endocrinology Letters (2004)
- Body composition and adiposity modulation Animal studies only
- Twice-daily s.c. ipamorelin induced a small (~15%) body weight increase and increased relative fat pad weights in both GH-deficient and GH-intact mice by 2 weeks, with increased serum leptin and food intake. Effects on adiposity were GH-independent. PMID 11162489 Lall S et al. Biochemical and Biophysical Research Communications (2001)
- Reproductive axis modulation (fish model) Animal studies only
- Ipamorelin acetate (5 or 30 µg for 21 days) in tilapia dose-dependently increased food intake, spermatocyte and spermatid numbers, and serum LH and 11-ketotestosterone concentrations. PMID 38996787 Gouda M, Ganesh CB. Animal Reproduction Science (2024)
- Pituitary somatotroph cell dynamics Animal studies only
- Chronic treatment with ipamorelin (21 days) in young female rats increased secretory granule volume density in somatotroph cells. In vitro ipamorelin (10⁻⁸ M) increased the percentage of somatotroph cells and intracellular GH content only in the ipamorelin-pretreated group. PMID 12168778 Jiménez-Reina L et al. Histology and Histopathology (2002)
Safety signals
- In the Phase II RCT (n=114), any treatment-emergent adverse events occurred in 87.5% of the ipamorelin group vs 94.8% of the placebo group; specific adverse events not detailed in abstract beyond nausea and vomiting endpoints. No significant safety differences from placebo were highlighted. PMID 25331030
- GH-independent increase in body fat (adiposity), increased food intake, and elevated serum leptin observed in mice treated with ipamorelin (s.c., twice daily), including in GH-intact animals. PMID 11162489
- Ipamorelin stimulates insulin secretion from pancreatic tissue of normal and diabetic rats in vitro, suggesting potential for glycemic effects. PMID 15665799
- Class-wide adverse effects reported for GHS/ipamorelin in self-administration literature include endocrine and metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. PMID 42395176
- Potential cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability reported as emerging risks associated with peptides in the GHS class including ipamorelin, particularly with supraphysiological or combined protocols common in bodybuilding. PMID 41880199
- Gray-market ipamorelin products are at risk of mislabeling or contamination; analogs such as Gly-Ipamorelin (an N-terminal glycine-extended analog) have been identified in seized doping materials, with unknown pharmacological and safety profiles. PMID 29864719
- Uncertain product composition, dose, and stacking practices in unregulated supply chains pose safety risks; biologically plausible but unproven mitogenic concerns are noted for GH axis-modulating peptides. PMID 42395176
- In streptozotocin-diabetic mice, ipamorelin IV injection produced substantially higher GH levels (150 ± 35 µg/L) compared to non-diabetic mice (62 ± 11 µg/L), suggesting unpredictable GH axis responses in diabetic subjects. PMID 14630569
Contraindications
- No specific contraindications are explicitly stated in the reviewed abstracts for ipamorelin. Use in patients with diabetes mellitus may produce unpredictable GH hypersecretion responses (demonstrated in streptozotocin-diabetic mice). PMID 14630569
- Use by competitive athletes is contraindicated under WADA rules, as ipamorelin is listed on the WADA Prohibited List. PMID 26578461
Protocol
200 mcg subcutaneous injection, once daily, pre-sleep. Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous infusion | 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes (5 dose levels) | Single infusion | human | Research PMID 10496658 |
| Intravenous infusion | 0.03 mg/kg twice daily | Up to 7 days (postoperative day 1–7 or hospital discharge) | human | Research PMID 25331030 |
| Subcutaneous injection | 0, 18, 90, and 450 µg/day (divided into 3 s.c. injections/day) | 15 days | animal | Research PMID 10373343 |
| Subcutaneous injection | 100 µg/kg three times daily | 3 months | animal | Research PMID 11735244 |
| Subcutaneous (osmotic minipump) | 0.5 mg/kg per day | 12 weeks | animal | Research PMID 10828840 |
| Not specified (parenteral, context of rat study) | 0.5 mg/kg/day | 7 days | animal | Research PMID 19231263 |
| Intravenous | 0.4 or 1.6 mg/kg/day (administered 4 times daily intravenously) | 10 days | animal | Research PMID 10629165 |
| Intravenous bolus infusion | 0.01–1 mg/kg (single dose) or 0.1–1 mg/kg (repetitive: 4 doses/day at 3-h intervals for 2 days) | Single dose or 2-day repetitive dosing | animal | Research PMID 19289567 |
| Intravenous (in vivo); organ bath (in vitro) | 0.014–0.14 µmol/kg; also 1 µM (in vitro organ bath) | Single dose | animal | Research PMID 27186127 |
| Intraperitoneal | 1–3 mg/kg | Up to 72 h (every 24 h dosing) | animal | Research PMID 39043357 |
| Not explicitly specified (administration to fish) | 5 or 30 µg per fish | 21 days | animal | Research PMID 38996787 |
| In vitro (pancreatic tissue fragments) | 10⁻¹²–10⁻⁶ M | In vitro incubation | in_vitro | Research PMID 15665799 |
| In vivo (route not specified); in vitro | 10⁻⁸ M (in vitro); chronic dosing regimen not specified numerically in abstract | 21 days (in vivo); 4 hours (in vitro) | animal | Research PMID 12168778 |
| Subcutaneous | Twice daily s.c. (exact dose not stated in abstract) | 2–9 weeks | animal | Research PMID 11162489 |
| Intravenous (rats, swine) | ED50 = 80 ± 42 nmol/kg (rats); ED50 = 2.3 ± 0.03 nmol/kg, Emax = 65 ± 0.2 ng GH/mL plasma (swine) | Single dose | animal | Research PMID 9849822 |
| Intravenous; intranasal | Pharmacokinetic doses (intranasal bioavailability ~20% in rats); exact doses not specified in abstract | Single dose | animal | Research PMID 9879640 |
| subcutaneous injection | 200 mcg | once daily, pre-sleep · 8-12 weeks | biohackers and fitness-focused adults seeking GH optimization | [Community] |
| subcutaneous injection | 300 mcg | once daily, pre-sleep · 8-12 weeks | biohackers and fitness-focused adults seeking GH optimization | [Community] |
| subcutaneous injection | 500 mcg | once daily, pre-sleep · 8-12 weeks | intermediate-to-advanced biohackers, bodybuilders | [Community] |
| subcutaneous injection | 300 mcg | three times daily (morning, post-workout, pre-sleep) · 8-12 weeks | bodybuilders and advanced biohackers chasing multiple GH pulses per day | [Community] |
| subcutaneous injection | 200 mcg | three times daily (morning, post-workout, pre-sleep) · 8-12 weeks | fitness-oriented adults, those cautious about side effects | [Community] |
| subcutaneous injection | 300 mcg | once daily, pre-sleep · 12-16 weeks | anti-aging biohackers and longevity-focused adults | [Community] |
| subcutaneous injection | 100 mcg | once daily, pre-sleep · 8-12 weeks | beginners, older adults, or those sensitive to GH secretagogues | [Community] |
| subcutaneous injection | 300 mcg | once daily, pre-sleep · 8-12 weeks | adults combining ipamorelin with CJC-1295 (no DAC) or Mod GRF 1-29 | [Community] |
| subcutaneous injection | 200 mcg | once daily, pre-sleep · 8-12 weeks | adults combining ipamorelin with CJC-1295 (no DAC) or Mod GRF 1-29; entry-level stackers | [Community] |
| subcutaneous injection | 300 mcg | three times daily (morning, post-workout, pre-sleep) · 8-12 weeks | advanced bodybuilders stacking ipamorelin with CJC-1295 (no DAC) | [Community] |
| subcutaneous injection | 300 mcg | once daily, pre-sleep · 8-12 weeks | post-injury or post-surgery adults seeking soft-tissue repair | [Community] |
| subcutaneous injection | 200 mcg | once daily, pre-sleep · 8-12 weeks | women using ipamorelin for body composition or anti-aging | [Community] |
| subcutaneous injection | 500 mcg | three times daily (morning, post-workout, pre-sleep) · 8-12 weeks | advanced male bodybuilders seeking aggressive GH output | [Community] |
Blends containing this peptide
All studies (26)
- PMID 19289567 Human RCT
Postoperative ileus / gastrointestinal motility - PMID 25331030 Human RCT
Postoperative ileus / gastrointestinal motility - PMID 27186127 Human RCT
Postoperative ileus / gastrointestinal motility - PMID 9849822 Mixed
Growth hormone stimulation / GH-IGF-1 axis modulation - PMID 10373343 Mixed
Growth hormone stimulation / GH-IGF-1 axis modulation - PMID 10496658 Mixed
Growth hormone stimulation / GH-IGF-1 axis modulation - PMID 9879640
Pharmacokinetic doses (intranasal bioavailability ~20% in rats); exact doses not specified in abstract Intravenous; intranasal (animal) - PMID 10629165 Animal studies only
Counteracting glucocorticoid-induced muscle and bone catabolism - PMID 10828840 Animal studies only
Bone mineral content and longitudinal bone growth - PMID 11162489 Animal studies only
Body composition and adiposity modulation - PMID 11735244 Animal studies only
Counteracting glucocorticoid-induced muscle and bone catabolism - PMID 12168778 Animal studies only
Pituitary somatotroph cell dynamics - PMID 14630569
In streptozotocin-diabetic mice, ipamorelin IV injection produced substantially higher GH levels (150 ± 35 µg/L) compared to non-diabetic mice (62 ± 11 µg/L), s - PMID 15665799 In vitro only
Insulin secretion stimulation - PMID 19231263 Animal studies only
Counteracting glucocorticoid-induced muscle and bone catabolism - PMID 25869809
- PMID 26578461
Use by competitive athletes is contraindicated under WADA rules, as ipamorelin is listed on the WADA Prohibited List. - PMID 29864719
Gray-market ipamorelin products are at risk of mislabeling or contamination; analogs such as Gly-Ipamorelin (an N-terminal glycine-extended analog) have been id - PMID 32257855 Animal studies only
Visceral and somatic pain attenuation - PMID 38996787 Animal studies only
Reproductive axis modulation (fish model) - PMID 39043357 Animal studies only
Cisplatin-induced weight loss and cachexia prevention - PMID 41476424 Animal studies only
Musculoskeletal recovery / performance enhancement (combined with CJC-1295) - PMID 41490200
- PMID 41880199
Potential cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability reported as emerging risks associated with peptides in the GHS cl - PMID 41966639
- PMID 42395176
Class-wide adverse effects reported for GHS/ipamorelin in self-administration literature include endocrine and metabolic disturbances (prolactin and cortisol el